Document:

Exhibit
      4.4

    

    THIS
      WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN ACQUIRED
      FOR
      INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
      AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. THIS WARRANT AND SUCH
      SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE PLEDGED, TRANSFERRED OR
      HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR DELIVERY OF AN OPINION
      OF
      COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
      OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE
      ACT
      OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER THE ACT.

    

    

    COUGAR
      BIOTECHNOLOGY, INC.

    

    

    

    Warrant
      for the Purchase of Shares of

    Common
      Stock

    

    
      	No.
              2005A-	
              ________
                Shares

            

    

     

    

    FOR
      VALUE
      RECEIVED, COUGAR BIOTECHNOLOGY, INC., a Delaware corporation (the “Company”),
      hereby certifies that _________________, its designee or its permitted assigns
      is entitled to purchase from the Company, at any time or from time to time
      commencing on January 24, 2006, and prior to 5:00 P.M., New York City time,
      on
      January 24, 2013 (the “Exercise
      Period”),
      ___________________________________________ (______) fully paid and
      non-assessable shares of common stock, $0.001 par value per share, of the
      Company for a purchase price per share of $3.18. 

    

    Hereinafter,
      (i) said common stock, $0.001 par value per share, of the Company, is referred
      to as the “Common
      Stock”;
      (ii)
      the shares of the Common Stock (subject to adjustment as set forth herein)
      purchasable hereunder or under any other Warrant (as hereinafter defined) are
      referred to as the “Warrant
      Shares”;
      (iii)
      the aggregate purchase price payable for the Warrant Shares purchasable
      hereunder is referred to as the “Aggregate
      Warrant Price”;
      (iv)
      the price payable (initially $3.18 per share subject to adjustment as set forth
      herein) for each of the Warrant Shares hereunder is referred to as the
“Per
      Share Warrant Price”;
      (v)
      this Warrant, all similar Warrants issued on the date hereof and all warrants
      hereafter issued in exchange or substitution for this Warrant or such similar
      Warrants are referred to as the “Warrants”;
      (vi)
      the holder of this Warrant is referred to as the “Holder”
and
      the
      holder of this Warrant and all other Warrants and Warrant Shares are referred
      to
      as the “Holders”
and
      Holders of more than fifty percent (50%) of the Warrant Shares then issuable
      upon exercise of then outstanding Warrants are referred to as the “Majority
      of the Holders”)
      and
      (vii) the then Current Market Price per share of the Common Stock (the
“Current
      Market Price”)
      shall
      be deemed to be the last reported sale price of the Common Stock on the Trading
      Day (as defined below) immediately prior to such date or, in case no such
      reported sales take place on such day, the average of the last reported bid
      and
      asked prices of the Common Stock on such day, in either case on the principal
      national securities exchange on which the Common Stock is admitted to trading
      or
      listed, or if not listed or admitted to trading on any such exchange, the
      representative closing sale price of the Common Stock as reported by the
      National Association of Securities Dealers, Inc. Automated Quotations System
      (“NASDAQ”),
      or
      other similar organization if NASDAQ is no longer reporting such information,
      or, if the Common Stock is not reported on NASDAQ, the per share sale price
      for
      the Common Stock in the over-the-counter market as reported by the National
      Quotation Bureau or similar organization, or if not so available, the fair
      market value of the Common Stock as determined in good faith by the Company’s
      Board of Directors. A “Trading
      Day”
shall
      mean any day on which shares of the Company’s Common Stock are sold on the
      respective exchange. The Aggregate Warrant Price is not subject to
      adjustment.

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    This
      Warrant, together with warrants of like tenor, constituting in the aggregate
      Warrants to purchase One
      Hundred Ninety-Three Thousand Two Hundred Forty-Three
      Warrant
      Shares, was originally issued pursuant to an Introduction Agreement (the
“Introduction
      Agreement”)
      between
      the Company and the Holder
      in
      connection with a private placement by the Company of certain senior convertible
      notes, as described in that certain Confidential Offering Memorandum dated
      October 7, 2005 (the “Offering”).
       

    

    I.  Exercise
      of Warrant. 

     

    A.  This
      Warrant may be exercised in whole at any time, or in part from time to time,
      by
      the Holder during the Exercise Period:

     

    1.  by
      the
      surrender of this Warrant (with the subscription form at the end hereof duly
      executed) at the address set forth in subsection 9(a) hereof, together with
      proper payment of the Aggregate Warrant Price, or the proportionate part thereof
      if this Warrant is exercised in part, with payment for the Warrant Shares made
      by certified or official bank check payable to the order of, or wire transfer
      of
      immediately available funds to, the Company; or

     

    2.  by
      the
      surrender of this Warrant (with the cashless exercise form at the end hereof
      duly executed) (a “Cashless Exercise”) at the address set forth in subsection
      9(a) hereof. Such presentation and surrender shall be deemed a waiver of the
      Holder’s obligation to pay the Aggregate Warrant Price, or the proportionate
      part thereof if this Warrant is exercised in part. In the event of a Cashless
      Exercise, the Holder shall exchange its Warrant for that number of Warrant
      Shares subject to such Cashless Exercise multiplied by a fraction, the numerator
      of which shall be the difference between the then Current Market Price and
      the
      Per Share Warrant Price, and the denominator of which shall be the then Current
      Market Price. For purposes of any computation under this subsection 1(a), the
      then Current Market Price shall be based on the Trading Day immediately
      preceding such Cashless Exercise.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    B.  If
      this
      Warrant is exercised in part, this Warrant must be exercised for a number of
      whole shares of the Common Stock and the Holder is entitled to receive a new
      Warrant covering the Warrant Shares that have not been exercised and setting
      forth the proportionate part of the Aggregate Warrant Price applicable to such
      Warrant Shares. Upon surrender of this Warrant in connection with the exercise
      of this Warrant pursuant to the terms hereof, the Company will (i) issue a
      certificate or certificates in the name of the Holder for the largest number
      of
      whole shares of the Common Stock to which the Holder shall be entitled upon
      such
      exercise and, if this Warrant is exercised in whole, in lieu of any fractional
      share of the Common Stock to which the Holder shall be entitled, pay to the
      Holder cash in an amount equal to the fair value of such fractional share
      (determined in such reasonable manner as the Board of Directors of the Company
      shall determine), and (ii) deliver the other securities and properties
      receivable upon the exercise of this Warrant, or the proportionate part thereof,
      if this Warrant is exercised in part, pursuant to the provisions of this
      Warrant. 

     

    II.  Reservation
      of Warrant Shares; Listing. 

     

    The
      Company agrees that, prior to the expiration of this Warrant, the Company shall
      at all times (a) have authorized and in reserve, and shall keep available,
      solely for issuance and delivery upon the exercise of this Warrant, the shares
      of the Common Stock and other securities and properties as from time to time
      shall be receivable upon the exercise of this Warrant, free and clear of all
      restrictions on sale or transfer, other than under Federal or state securities
      laws, and free and clear of all preemptive rights and rights of first refusal
      and (b) if the Company hereafter lists its Common Stock on any national
      securities exchange, the NASDAQ National Market or the NASDAQ Smallcap Market,
      use its commercially reasonable efforts to keep the Warrant Shares authorized
      for listing on such exchange upon notice of issuance.

    

    III.  Certain
      Adjustments. 

     

    A.  If,
      at
      any time or from time to time after the date of this Warrant, the Company shall
      issue or distribute to all holders of shares of Common Stock by reason of their
      ownership thereof evidence of its indebtedness, any other securities of the
      Company or any cash, property or other assets (excluding a subdivision,
      combination or reclassification, or dividend or distribution payable in shares
      of Common Stock, referred to in subsection 3(b), and also excluding cash
      dividends or cash distributions paid out of net profits legally available
      therefor (any such non-excluded event being herein called a “Special
      Dividend”)),
      the
      Per Share Warrant Price shall be adjusted (effective immediately prior to such
      issuance or distribution but after the record date for such issuance or
      distribution) by multiplying the Per Share Warrant Price then in effect by
      a
      fraction, the numerator of which shall be the Current Market Price in effect
      on
      the record date for such issuance or distribution less the fair market value
      (as
      determined in good faith by the Company’s Board of Directors) of the evidence of
      indebtedness, cash, securities or property, or other assets issued or
      distributed in such Special Dividend applicable to one share of Common Stock
      and
      the denominator of which shall be the Current Market Price in effect on the
      record date for such issuance or distribution. An adjustment made pursuant
      to
      this subsection 3(a) shall become effective immediately prior to the payment
      date but after the record date of any such Special Dividend. If such dividend,
      distribution, subdivision or combination is not consummated in full, the Per
      Share Warrant Price and Warrant Shares shall be readjusted
      accordingly.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    B.  In
      case
      the Company shall hereafter (i) pay a dividend or make a distribution on its
      Common Stock in shares of Common Stock, (ii) subdivide its outstanding shares
      of
      Common Stock into a greater number of shares, (iii) combine or reverse-split
      its
      outstanding shares of Common Stock into a smaller number of shares or (iv)
      issue
      by reclassification of its Common Stock any shares of capital stock of the
      Company, then the Per Share Warrant Price and the number of Warrant Shares
      shall
      forthwith be proportionately decreased and increased, respectively, in the
      case
      of a subdivision, distribution or stock dividend, or proportionately increased
      and decreased, respectively, in the case of a combination or reverse stock
      split. The Aggregate Warrant Price payable for the then total number Warrant
      Shares available for exercise under this Warrant shall remain the same.
      Adjustments made pursuant to this subsection 3(b) shall become effective on
      the
      record date in the case of a dividend or distribution, and shall become
      effective immediately after the effective date in the case of a subdivision,
      combination or reclassification. If such dividend, distribution, subdivision
      or
      combination is not consummated in full, the Per Share Warrant Price and Warrant
      Shares shall be readjusted accordingly.

     

    C.  In
      case
      of any capital reorganization or reclassification, or any consolidation or
      merger to which the Company is a party other than a merger or consolidation
      in
      which the Company is the continuing corporation, or in case of any sale or
      conveyance to another entity of all or substantially all of the assets of the
      Company, or in the case of any statutory exchange of securities with another
      corporation (including any exchange effected in connection with a merger of
      a
      third corporation into the Company but excluding any exchange of securities
      or
      merger with another corporation in which the Company is a continuing corporation
      and that does not result in any reclassification of or similar change in the
      Common Stock), the Holder of this Warrant shall have the right thereafter to
      receive on the exercise of this Warrant the kind and amount of securities,
      cash
      or other property which the Holder would have owned or have been entitled to
      receive immediately after such reorganization, reclassification, consolidation,
      merger, statutory exchange, sale or conveyance had this Warrant been exercised
      immediately prior to the effective date of such reorganization,
      reclassification, consolidation, merger, statutory exchange, sale or conveyance
      and in any such case, if necessary, appropriate adjustment shall be made in
      the
      application of the provisions set forth in this Section 3 with respect to the
      rights and interests thereafter of the Holder of this Warrant to the end that
      the provisions set forth in this Section 3 shall thereafter correspondingly
      be
      made applicable, as nearly as may reasonably be, in relation to any shares
      of
      stock or other securities or property thereafter deliverable on the exercise
      of
      this Warrant. The above provisions of this subsection 3(c) shall similarly
      apply
      to successive reorganizations, reclassifications, consolidations, mergers,
      statutory exchanges, sales or conveyances. The Company shall require the issuer
      of any shares of stock or other securities or property thereafter deliverable
      on
      the exercise of this Warrant to be responsible for all of the agreements and
      obligations of the Company hereunder. Notice of any such reorganization,
      reclassification, consolidation, merger, statutory exchange, sale or conveyance
      and of said provisions so proposed to be made, shall be mailed to the Holders
      of
      the Warrants not less than twenty (20) days prior to such event. A sale of
      all
      or substantially all of the assets of the Company for a consideration consisting
      primarily of securities shall be deemed a consolidation or merger for the
      foregoing purposes.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    D.  No
      adjustment in the Per Share Warrant Price shall be required unless such
      adjustment would require an increase or decrease of at least $0.03 per share
      of
      Common Stock; provided,
      however,
      that
      any adjustments which by reason of this subsection 3(d) are not required to
      be
      made shall be carried forward and taken into account in any subsequent
      adjustment; provided,
      further,
      however, that adjustments shall be required and made in accordance with the
      provisions of this Section 3 (other than this subsection 3(d)) not later than
      such time as may be required in order to preserve the tax-free nature of a
      distribution, if any, to the Holder of this Warrant or Common Stock issuable
      upon the exercise hereof. All calculations under this Section 3 shall be made
      to
      the nearest cent or to the nearest 1/100th of a share, as the case may be.
      Anything in this Section 3 to the contrary notwithstanding, the Company shall
      be
      entitled to make such reductions in the Per Share Warrant Price, in addition
      to
      those required by this Section 3, as it in its discretion shall deem to be
      advisable in order that any stock dividend, subdivision of shares or
      distribution of rights to purchase stock or securities convertible or
      exchangeable for stock hereafter made by the Company to its stockholders shall
      not be taxable.

     

    E.  Whenever
      the Per Share Warrant Price is adjusted as provided in this Section 3 and upon
      any modification of the rights of a Holder of Warrants in accordance with this
      Section 3, the Company shall promptly prepare a brief statement of the facts
      requiring such adjustment or modification and the manner of computing the same
      and cause copies of such certificate to be mailed to the Holders of the
      Warrants. The Company may, but shall not be obligated to unless requested by
      a
      Majority of the Holders, obtain, at its expense, a certificate of a firm of
      independent public accountants of recognized standing selected by the Board
      of
      Directors (who may be the regular auditors of the Company) setting forth the
      Per
      Share Warrant Price and the number of Warrant Shares in effect after such
      adjustment or the effect of such modification, a brief statement of the facts
      requiring such adjustment or modification and the manner of computing the same
      and cause copies of such certificate to be mailed to the Holders of the
      Warrants.

     

    F.  If
      the
      Board of Directors of the Company shall declare any dividend or other
      distribution with respect to the Common Stock other than a cash distribution
      out
      of earned surplus, the Company shall mail notice thereof to the Holders of
      the
      Warrants not less than ten (10) days prior to the record date fixed for
      determining stockholders entitled to participate in such dividend or other
      distribution.

     

    G.  If,
      as a
      result of an adjustment made pursuant to this Section 3, the Holder of any
      Warrant thereafter surrendered for exercise shall become entitled to receive
      shares of two or more classes of capital stock or shares of Common Stock and
      other capital stock of the Company, the Board of Directors (whose determination
      shall be conclusive and shall be described in a written notice to the Holder
      of
      any Warrant promptly after such adjustment) shall determine,
      in good
      faith,
      the
      allocation of the adjusted Per Share Warrant Price between or among shares
      or
      such classes of capital stock or shares of Common Stock and other capital
      stock.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    H.  Upon
      the
      expiration of any rights, options, warrants or conversion privileges with
      respect to the issuance of which an adjustment to the Per Share Warrant Price
      had been made, if such option, right warrant or conversion shall not have been
      exercised, the number of Warrant Shares purchasable upon exercise of this
      Warrant, to the extent this Warrant has not then been exercised, shall, upon
      such expiration, be readjusted and shall thereafter be such as they would have
      been had they been originally adjusted (or had the original adjustment not
      been
      required, as the case may be) on the basis of (A) the fact that Common Stock,
      if
      any, actually issued or sold upon the exercise of such rights, options, warrants
      or conversion privileges, and (B) the fact that such shares of Common Stock,
      if
      any, were issued or sold for the consideration actually received by the Company
      upon such exercise plus the consideration, if any, actually received by the
      Company for the issuance, sale or grant of all such rights, options, warrants
      or
      conversion privileges whether or not exercised; provided,
      however,
      that no
      such readjustment shall have the effect of decreasing the number of Warrant
      Shares purchasable upon exercise of this Warrant by an amount in excess of
      the
      amount of the adjustment initially made in respect of the issuance, sale or
      grant of such rights, options, warrants or conversion privileges.

     

    I.  In
      case
      any event shall occur as to which the other provisions of this Section 3 are
      not
      strictly applicable but as to which the failure to make any adjustment would
      not
      fairly protect the purchase rights represented by this Warrant in accordance
      with the essential intent and principles of the adjustments set forth in this
      Section 3 then, in each such case, the Board of Directors of the Company shall
      in good faith determine the adjustment, if any, on a basis consistent with
      the
      essential intent and principles established herein, necessary to preserve the
      purchase rights represented by the Warrants. Upon such determination, the
      Company will promptly mail a copy thereof to the Holder of this Warrant and
      shall make the adjustments described therein.

     

    IV.  Fully
      Paid Stock; Taxes.

     

    The
      shares of the Common Stock represented by each and every certificate for Warrant
      Shares delivered on the exercise of this Warrant shall, subject to compliance
      by
      the Holder with the terms hereof, at the time of such delivery, be duly
      authorized, validly issued and outstanding, fully paid and nonassessable, and
      not subject to preemptive rights or rights of first refusal imposed by any
      agreement to which the Company is a party, and the Company will take all such
      actions as may be necessary to assure that the par value, if any, per share
      of
      the Common Stock is at all times equal to or less than the then Per Share
      Warrant Price. The Company shall pay, when due and payable, any and all Federal
      and state stamp, original issue or similar taxes which may be payable in respect
      of the issue of any Warrant Share or any certificate thereof to the extent
      required because of the issuance by the Company of such security.

    

    V.  Registration
      Under Act. 

     

    A.  The
      Holder shall have the right to participate in the registration rights granted
      to
      purchasers in the Offering pursuant to Article V of those certain Note and
      Warrant Purchase Agreements by and between the Company and each such purchaser.
      

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    B.  Until
      all
      of the Warrant Shares and any shares of Common Stock issuable thereunder have
      been sold under a Registration Statement or pursuant to Rule 144(k), so long
      as
      the Company’s Common Stock remains registered under the Act, the Company shall
      use its commercially reasonable efforts to file with the Securities and Exchange
      Commission all current reports and the information as may be necessary to enable
      the Holder to effect sales of its shares in reliance upon Rule 144(k)
      promulgated under the Act.

     

    VI.  Investment
      Intent; Limited Transferability. 

     

    A.  By
      accepting this Warrant, the Holder represents to the Company that it understands
      that this Warrant and any securities obtainable upon exercise of this Warrant
      have not been registered for sale under Federal or state securities laws and
      are
      being offered and sold to the Holder pursuant to one or more exemptions from
      the
      registration requirements of such securities laws. In the absence of an
      effective registration of such securities or an exemption therefrom, any
      certificates for such securities shall bear the legend set forth on the first
      page hereof. The Holder understands that it must bear the economic risk of
      its
      investment in this Warrant and any securities obtainable upon exercise of this
      Warrant for an indefinite period of time, as this Warrant and such securities
      have not been registered under Federal or state securities laws and therefore
      cannot be sold unless subsequently registered under such laws, unless an
      exemption from such registration is available. The Holder further represents
      to
      the Company, by accepting this Warrant, that it has full power and authority
      to
      accept this Warrant and make the representations set forth herein.

     

    B.  The
      Holder, by its acceptance of this Warrant, represents to the Company that it
      is
      acquiring this Warrant and will acquire any securities obtainable upon exercise
      of this Warrant for its own account for investment and not with a view to,
      or
      for sale in connection with, any distribution thereof in violation of the Act.
      The Holder agrees, by acceptance of this Warrant, that this Warrant and any
      such
      securities issuable
      under this Warrant will
      not
      be sold or otherwise transferred unless
      (i) a registration statement with respect to such transfer is effective under
      the Act and any applicable state securities laws or (ii) such sale or transfer
      is made pursuant to one or more exemptions from the Act. 

     

    C.  In
      addition to the limitations set forth in Section 1 and in accordance with the
      legend on the first page hereof, this Warrant may not be sold, transferred,
      assigned or hypothecated by the Holder except in compliance with the provisions
      of the Act and the applicable state securities “blue sky” laws, and is so
      transferable only upon the books of the Company which it shall cause to be
      maintained for such purpose. The Company may treat the registered Holder of
      this
      Warrant as it appears on the Company’s books at any time as the Holder for all
      purposes. The Company shall permit any Holder of a Warrant or its duly
      authorized attorney, upon written request during ordinary business hours, to
      inspect and copy or make extracts from its books showing the registered Holders
      of Warrant. All Warrants issued upon the transfer or assignment of this Warrant
      will be dated the same date as this Warrant, and all rights of the holder
      thereof shall be identical to those of the Holder unless, in each case,
      otherwise prohibited by applicable law.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    D.  The
      Holder has been afforded (i) the opportunity to ask such questions as it has
      deemed necessary of, and to receive answers from, representatives of the Company
      concerning the terms and conditions of the Warrants or the exercise of the
      Warrants; and (ii) the opportunity to request such additional information which
      the Company possesses or can acquire without unreasonable effort or
      expense.

     

    E.  The
      Holder did not (i) receive or review any advertisement, article, notice or
      other
      communication published in a newspaper or magazine or similar media or broadcast
      over television or radio, whether closed circuit, or generally available; or
      (ii) attend any seminar, meeting or investor or other conference whose attendees
      were, to such Holder’s knowledge, invited by any general solicitation or general
      advertising.

     

    F.  The
      Holder is an “accredited investor” within the meaning of Regulation D under the
      Act. Such Holder is acquiring the Warrants for its own account and not with
      a
      present view to, or for sale in connection with, any distribution thereof in
      violation of the registration requirements of the Act, without prejudice,
      however, to such Holder’s right, subject to the provisions of the Introduction
      Agreement and this Warrant, at all times to sell or otherwise dispose of all
      or
      any part of such Warrants and Warrant Shares.

     

    G.  Either
      by
      reason of such Holder’s business or financial experience or the business or
      financial experience of its professional advisors (who are unaffiliated with
      and
      who are not compensated by the Company or any affiliate, finder or selling
      agent
      of the Company, directly or indirectly), such Holder has the capacity to protect
      such Holder’s interests in connection with the transactions contemplated by this
      Warrant and the Introduction
      Agreement. The Holder, by its acceptance of this Warrant, represents to the
      Company that it is able to fend for itself, can bear the economic risk of its
      investment and has such knowledge and experience in financial or business
      matters that it is capable of evaluating the merits and risks of the investment
      in this Warrant. Holder also represents it has not been organized for the
      purpose of acquiring this Warrant.

     

    VII.  Loss,
      etc., of Warrant.

     

    Upon
      receipt of evidence reasonably satisfactory to the Company of the loss, theft,
      destruction or mutilation of this Warrant, and of indemnity reasonably
      satisfactory to the Company, if lost, stolen or destroyed, and upon surrender
      and cancellation of this Warrant, if mutilated, the Company shall execute and
      deliver to the Holder a new Warrant of like date, tenor and
      denomination.

    

    VIII.  Warrant
      Holder Not Stockholder.

     

    This
      Warrant does not confer upon the Holder any right to vote on or consent to
      or
      receive notice as a stockholder of the Company, as such, in respect of any
      matters whatsoever, nor any other rights or liabilities as a stockholder, prior
      to the exercise hereof; this Warrant does, however, require certain notices
      to
      Holders as set forth herein.

    

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    IX.  Communication.

     

    No
      notice
      or other communication under this Warrant shall be effective or deemed to have
      been given unless, the same is in writing and is mailed by first-class mail,
      postage prepaid, or via recognized overnight courier with confirmed receipt,
      addressed to:

    

    A.  the
      Company at Cougar Biotechnology, Inc., 10940 Wilshire Boulevard, Suite 600,
      Los
      Angeles, California 90024, Attn: President, or other such address as the Company
      has designated in writing to the Holder, or

     

    B.  the
      Holder at c/o Paramount BioCapital, Inc., 787 Seventh Avenue, 48th
      Floor,
      New York, New York 10019, or other such address as the Holder has designated
      in
      writing to the Company.

     

    X.  Headings.

     

    The
      headings of this Warrant have been inserted as a matter of convenience and
      shall
      not affect the construction hereof.

    

    XI.  Applicable
      Law.

     

    This
      Warrant shall be governed by and construed in accordance with the law of the
      State of Delaware without giving effect to the principles of conflicts of law
      thereof.

    

    XII.  Amendment,
      Waiver, etc.

     

    Except
      as
      expressly provided herein, neither this Warrant nor any term hereof may be
      amended, waived, discharged or terminated other than by a written instrument
      signed by the party against whom enforcement of any such amendment, waiver,
      discharge or termination is sought; provided, however, that any provisions
      hereof may be amended, waived, discharged or terminated upon the written consent
      of the Company and the Majority of the Holders.

    

    *
      * * *
      *

    

    Signature
      Page Follows

    

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    IN
      WITNESS WHEREOF,
      the
      Company has caused this Warrant to be signed by the undersigned duly authorized
      officer, this 24th
      of
      January, 2006.

    

    
      	 	 	 
	 	COUGAR
              BIOTECHNOLOGY, INC.
	 
 	 
 	 
 
	 	By:  	 
	 	
              
Name:
 Alan
              H. Auerbach
	 	Title:
               Chief
              Executive Officer

    

    

    

      Signature
        Page

      Cougar
        Biotechnology, Inc. Warrant No. 2005A-__

    

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    
 

    SUBSCRIPTION
      (cash)

     

    

    The
      undersigned, ___________________, pursuant to the provisions of the foregoing
      Warrant, hereby agrees to subscribe for and purchase ____________________ shares
      of the Common Stock, par value $0.001 per share, of Cougar Biotechnology, Inc.
      covered by said Warrant, and makes payment therefor in full at the price per
      share provided by said Warrant.

    

     

    
      	Dated: _______________	Signature:
              __________________________
	 	 
	 	Address:
              ___________________________

    

     

     

    CASHLESS
      EXERCISE

     

    

    The
      undersigned _____________, pursuant to the provisions of the foregoing Warrant,
      hereby elects to exchange its Warrant for ___________________ shares of Common
      Stock, par value $0.001 per share, of Cougar Biotechnology, Inc. pursuant to
      the
      Cashless Exercise provisions of the Warrant.

    

    
       

      
        	Dated: _______________	Signature:
                __________________________
	 	 
	 	Address:
                ___________________________

      

       

      

    

    

      Warrant
        No. 2005A-__, dated January 24, 2006 (the “Warrant”)

       

      
        
           

        

        
          11

          
            

          

        

        
           

        

      

    ASSIGNMENT

     

    

    FOR
      VALUE
      RECEIVED _______________ (“Assignor”) hereby sells, assigns and transfers unto
      ____________________ (“Transferee”) the foregoing Warrant and all rights
      evidenced thereby, and does irrevocably constitute and appoint
      _____________________, attorney, to transfer said Warrant on the books of Cougar
      Biotechnology, Inc. By acceptance of the foregoing Warrant, Transferee shall
      become a Holder under said Warrant and subject to the rights, obligations and
      representations of Holder set forth in said Warrant.

    

    ASSIGNOR:

    
       

      
        	Dated: _______________	Signature:
                __________________________
	 	 
	 	Address:
                ___________________________

      

       

    

    TRANSFEREE:

    
       

      
        	Dated: _______________	Signature:
                __________________________
	 	 
	 	Address:
                ___________________________

      

       

    

    

    PARTIAL
      ASSIGNMENT

     

    

    FOR
      VALUE
      RECEIVED _______________ (“Assignor”) hereby assigns and transfers unto
      ____________________ (“Transferee”) the right to purchase _______ shares of
      Common Stock, par value $0.001 per share, of Cougar Biotechnology, Inc. covered
      by the foregoing Warrant, and a proportionate part of said Warrant and the
      rights evidenced thereby, and does irrevocably constitute and appoint
      ____________________, attorney, to transfer such part of said Warrant on the
      books of Cougar Biotechnology, Inc. By acceptance of the proportionate part
      of
      foregoing Warrant, Transferee shall become a Holder under said proportionate
      part of said Warrant and subject to the rights, obligations and representations
      of Holder set forth in said Warrant.

    

    ASSIGNOR:

    
       

      
        	Dated: _______________	Signature:
                __________________________
	 	 
	 	Address:
                ___________________________

      

       

       

    

    TRANSFEREE:

    
       

      
        	Dated: _______________	Signature:
                __________________________
	 	 
	 	Address:
                ___________________________

      

       

      
 

    

    

    Warrant
      No. 2005A-__ dated January 24, 2006 (the “Warrant”)

    

    
      
         

      

      
        12Exhibit
      10.1

     

    

     

    STOCK
      PURCHASE AGREEMENT

     

    THIS
      STOCK PURCHASE AGREEMENT ("Agreement")
      is
      entered into as of May 16, 2003, by and between HORIZON BIOMEDICAL INVESTMENTS,
      LLC (the "Purchaser") and COUGAR BIOTECHNOLOGY, INC., a Delaware Corporation
      having a business address at 787 Seventh Avenue, New York, NY 10019 (the
      "Corporation").

     

    RECITALS

     

    WHEREAS,
      the Corporation desires to sell shares of common stock, par value $.001 per
      share, of the Corporation (which class of shares is referred to herein as
      "Common
      Stock")
      to
      Purchaser, and Purchaser desires to purchase these shares, upon the terms and
      conditions herein specified; and

     

    WHEREAS,
      Purchaser is willing to subject the Stock (as defined herein) to the
      restrictions contained herein.

     

    AGREEMENT

     

    NOW,
      THEREFORE, in consideration of the foregoing recitals and of the mutual promises
      herein contained, the parties hereby agree as follows:

     

    1. Issuance
      and Acquisition of Stock.

     

    (a) Immediately
      after the execution of this Agreement by the parties, the Corporation shall
      transfer to the Purchaser, and the Purchaser shall acquire from the Corporation,
      the number of shares of Common Stock listed beside the Purchaser's name on
      the
      signature page hereto (the "Stock"), at
      the
      purchase price of $0.1765
      per
      share, for the total purchase price listed below the Purchaser's name on the
      signature page hereto (the "Purchase
      Price ").

     

    (b) As
      soon
      as reasonably practicable after the execution of this Agreement, the Corporation
      shall deliver to the Purchaser a certificate or certificates evidencing the
      Stock, registered in the name of the Purchaser and concurrently therewith the
      Purchaser shall make payment for the Stock by delivering to
      the
      Seller a check payable to the Corporation in the amount of the Purchase
      price.

     

    2. Violation
      Of Transfer Provisions.
      The
      Corporation shall not be required (i) to transfer on its books any shares of
      Stock which shall have been sold, transferred, assigned or pledged in violation
      of any of the provisions of this Agreement or
      (ii)
      to treat as owner of
      such
      shares or to accord the right to vote as such owner or to pay dividends to
      any
      transferee to whom such shares shall have been so sold, transferred, assigned
      or
      pledged.

    

    3. Rights
      as Shareholder. Except
      as
      otherwise provided herein, the Purchaser shall, during the term of this
      Agreement, exercise all rights and privileges of a shareholder of the
      Corporation with respect to the Stock.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    4. Representations
      and Warranties by the Corporation.

     

    The
      Corporation represents, warrants and covenants with the Purchaser as
      follows:

     

    (a) The
      Corporation has all necessary power and capacity to execute and deliver this
      Agreement, to perform its obligations hereunder and to consummate the
      transaction contemplated hereby. This Agreement has been validly executed and
      delivered by the Corporation and constitutes the legal, valid and binding
      obligation of
      the
      Corporation, enforceable
      against the Corporation
      in accordance with its terms. The execution and delivery of this Agreement
      by
      the Corporation do not and the performance of its obligations under this
      Agreement will not conflict with or result in any breach or constitute a default
      under any contracts
      to which the
      Corporation is a party or by which the Corporation or any property or asset
      of
      the Corporation is bound or affected.

     

    (b) The
      Corporation has good title to the Stock and owns the Stock free and clear of
      any
      security interests, liens, claims, pledges, options, rights of first refusal,
      agreements, limitations on voting rights, charges and other encumbrances of
      any
      nature whatsoever (collectively, "Liens")
      other
      than restrictions on transfer imposed under the Securities Act of 1933, as
      amended (the "Securities
      Act").
      Upon
      delivery thereof to the Purchaser, the Purchaser shall acquire good title to
      the
      Stock, free and clear of any Liens other than the restrictions set forth in
      this
      Agreement and under the Securities Act. The Stock is validly issued, fully
      paid
      and nonassessable. The Corporation is transferring the Stock to the Purchaser
      hereunder pursuant to a valid exemption from registration under the Securities
      Act.

     

    5. Representations
      and Warranties by the Purchaser.

     

    The
      Purchaser represents, warrants and covenants with the Corporation as
      follows:

     

    (a) The
      Purchaser has all necessary power and capacity to execute and deliver this
      Agreement, to perform its obligations hereunder and to consummate the
      transaction contemplated hereby. This Agreement has been validly executed and
      delivered by the Purchaser and constitutes the legal, valid and binding
      obligation of the Purchaser, enforceable against the Purchaser in accordance
      with its terms. The execution and delivery of this Agreement by
      the
      Purchaser do not and the performance of its obligations under this Agreement
      will not conflict with or result in any breach or constitute a default under
      any
      contracts to which the Purchaser is a party or by
      which
      the Purchaser or any property or asset of the Purchaser is bound or
      affected.

     

    (b) The
      Stock
      will be acquired by the Purchaser for his own account with the Purchaser's
      own
      funds for investment purposes and for the Purchaser's own account, not as a
      nominee or agent for any other person, firm or corporation, and not with a
      view
      to the sale or distribution of all or any part thereof, and the Purchaser has
      no
      present intention of selling, granting any participation in, or otherwise
      distributing, any or all of the Stock. The Purchaser does not have any contract,
      undertaking, agreement or arrangement with any person, firm or corporation
      to
      sell, transfer or grant any participation to any person, firm or corporation
      with respect to any or all of the Stock.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    (c) The
      Purchaser understands that the Stock will not be registered under the Securities
      Act of 1933, as amended (the "Securities
      Act"),
      and
      that the Stock is being issued and sold to the Purchaser based upon an exemption
      from registration predicated in part on the accuracy and completeness of the
      Purchaser's representations and warranties appearing herein.

     

    (d) The
      Purchaser agrees that in no event will the Purchaser sell, transfer,
      assign or
      pledge
      all or any part of the Stock or any interest therein, unless and until (i)
      the
      Purchaser shall have furnished the Corporation with an opinion of counsel
      satisfactory in form and content to the Corporation to the effect that (A)
      such
      disposition will not require registration of the Stock under the Securities
      Act
      or compliance with applicable state securities laws, or (B) appropriate action
      necessary for compliance with the Securities Act and applicable state securities
      laws has been taken; (ii) the Corporation shall have waived, expressly and
      in
writing,
      its right under clause (i) of this subsection; and (iii) the proposed
transferee
      of the Stock shall have provided the Corporation with a written agreement or
      undertaking by which such transferee agrees to be bound by all terms, conditions
      and limitations of this Agreement applicable to such transferee's transferor
      as
      if such transferee were a party hereto. The
      requirement of subparagraph (iii) shall not apply to any transfer (A) pursuant
      to an offering registered under the Securities Act, (B) pursuant to Rule 144
      under the Securities Act or (C) effected in a market transaction otherwise
      exempt from registration under the Securities Act.

     

    (e) The
      Purchaser is able to fend for itself in connection with the transactions
      contemplated by this Agreement, has such knowledge and experience in financial
      and business matters (including investments in development stage biotechnology
      companies) as to be capable of evaluating the merits and risks of its investment
      in the Corporation, has the ability to bear the economic risks of its investment
      for an indefinite period of time and can afford a complete loss of its
      investment and has had the opportunity prior to the Purchaser's purchase of
      the
      Stock to ask questions of and receive answers from representatives of the
      Corporation concerning the finances, operations and business of the Corporation.
      The Purchaser acknowledges and agrees that (i) it is not relying upon any
      statement, promise or assurance of the Corporation or any investor in the
      Corporation (or any representative of the Corporation or any such investor)
      in
      arriving at the Purchaser's decision to purchase the Stock, and has not
      otherwise been induced to purchase the Stock by the Corporation or any such
      investor (or any representative of the Corporation or any such investor); and
      that (ii) it has decided to purchase the Stock based upon the Purchaser's own
      analysis of the merits and risks of investing in the Corporation without the
      intervention or assistance of any other person, firm or
      corporation.

    

    (f) The
      Purchaser understands and acknowledges that the Purchaser will not be permitted
      to sell, transfer, assign or pledge the Stock until it is registered under
      the
      Securities Act or an exemption from the registration and prospectus delivery
      requirements of the Securities Act is available to the Purchaser, and that
      there
      is no assurance that such an exemption from registration will ever be available
      or that the Purchaser will ever be able to sell any of the Stock.

     

    (g) All
      certificates representing the Stock and, until such time as the Stock is sold
      in
      an offering which is registered under the Securities Act or the Corporation
      shall have received an opinion of counsel satisfactory in form and
      content to the Corporation that such registration is not required in connection
      with a resale (or subsequent resale) of the Stock, all certificates issued
      in
      transfer thereof or substitution therefor, shall, where applicable, have
      endorsed thereon the following (or substantially equivalent)
      legends:

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    (i) THE
      SECURITIES REPRESENTED BY THIS CERTIFICATE ARE NOT TRANSFERABLE WITHOUT THE
      EXPRESS WRITTEN CONSENT OF HUDSON HEALTH SCIENCES, INC., (THE "COMPANY") AND
      HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY APPLICABLE
      STATE SECURITIES OR "BLUE SKY" LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE,
      PLEDGED OR HYPOTHECATED OR OTHERWISE TRANSFERRED IN
      THE
      ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES
      UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
      REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.
      ANY SUCH TRANSFER MAY ALSO BE SUBJECT TO APPLICABLE STATE SECURITIES OR "BLUE
      SKY" LAWS.

     

    (ii) Any
      legend required to be placed thereon by any applicable state securities
      law.

     

    (h) The
      Corporation shall not be obligated to transfer any of the Stock if counsel
      for the Corporation determines that any applicable registration requirement
      under the Securities Act
      or
      any other applicable requirement of federal or state law has not been
      met.

     

    6. General
      Provisions.

     

    (a) No
      Assignments.
      The
      Purchaser shall not transfer, assign or encumber any of its rights, privileges,
      duties or obligations under this Agreement without the prior written consent
      of
      the Corporation, and any attempt to so transfer, assign or encumber shall be
      void.

    

    (b) Notices.
      All
      notices and other communications which are required or permitted to be given
      pursuant to the terms of this Agreement shall be in writing and shall be
      sufficiently given (i) if personally delivered, (ii) if sent by telex or
      facsimile, provided that "answer-back" confirmation is received by the sender
      or
      (iii) upon receipt, if sent by registered or certified mall, postage paid return
      receipt requested in any case addressed as follows:

     

    (i) If
      to the
      Corporation:

     

    Cougar
      Biotechnology, Inc. 787 Seventh Avenue

    New
      York,
      NY 10019 

    Att.: David
      M.
      Tanen Secretary

    

    (ii) If
      to the
      Purchaser, to the address set forth on the signature page of this
      Agreement.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    The
      address of a party, for the purposes of this Section 6(b)(ii), may be changed
      by
      giving written notice to the other party of such change in the manner provided
      herein for giving notice. Unless and until such written notice is received,
      the
      addresses as provided herein shall be deemed to continue in effect for all
      purposes hereunder.

     

    (c) Standoff
      Agreement. The
      Purchaser agrees that, in connection with each underwritten public offering
      registered under the Securities Act of shares of Common Stock or other equity
      securities of the Corporation by or on behalf of the Corporation, the Purchaser
      shall not sell or transfer, or offer to sell or transfer, any shares of Common
      Stock or other equity securities of the Corporation for such period as the
      managing underwriter of such offering or the Corporation determines is necessary
      to effect the underwritten public offering.

     

    (d) Choice
      of Law; Consent to Jurisdiction.
      This
      Agreement shall be governed by and construed in accordance with the internal
      laws (without giving effect to the conflicts of law principles) of the State
      of
      New York.

     

    (e) Severability. The
      parties hereto agree that the terms and provisions in this Agreement are
      reasonable and shall be binding and enforceable in accordance with the terms
      hereof and, in any event, that the terms and provisions of this Agreement shall
      be enforced to the fullest extent permissible under law. In the event that
      any
      term or provision of this Agreement shall for any reason be adjudged to be
      unenforceable or invalid, then such unenforceable or invalid term or provision
      shall not affect the enforceability or validity of the remaining terms and
      provisions of this Agreement, and the parties hereto hereby agree to replace
      such unenforceable or invalid term or provision with an enforceable and valid
      arrangement which, in its economic effect, shall be as close as possible to
      the
      unenforceable or invalid term or provision.

    

    (f) Successors. All
      references in this Agreement to the Corporation shall include any and all
      successors in interest to the Corporation, whether by merger, consolidation,
      sale of all or substantially all assets or otherwise, and this Agreement shall
      inure to the benefit of the successors and assigns of the Corporation and,
      subject to the terms herein set forth, shall be binding upon the Purchaser,
      its
      successors and permitted assigns.

     

    (g) Counterparts.
      This
      Agreement may be
      executed in two counterparts, each of which shall be deemed an original, but
      which together shall
      constitute
      one and the same instrument.

     

    (h) Modification,
      Amendment and Waiver.
      No
      modification, amendment or waiver of any provision of this Agreement shall
      be
      effective against the Corporation unless the same shall be in a written
      instrument signed by an officer of the Corporation on its behalf and such
      instrument is approved by its Board of Directors. The
      failure at any time to enforce any of the provisions of this Agreement shall
      in
      no way be construed as a waiver of such provisions and shall not affect the
      right of either party thereafter to enforce each and every provision hereof
      in
      accordance with its terms.

     

    (i) Further
      Assurances.
      The
      parties agree to execute such further instruments and to take such further
      action as may reasonably be necessary to carry out the intent of this
      Agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    (j) Integration.
      This
      Agreement constitutes the entire agreement of the parties with respect to the
      subject matter hereof.

     

    (k) Headings. The
      headings of the Sections and paragraphs of this Agreement have been inserted
      for
      convenience of reference only and do not constitute a part of this
      Agreement.

     

    (1) Gender
      and Number.
      As used
      in this Agreement, the masculine, feminine or neuter gender, and the singular
      or
      plural, shall be deemed to
      include the others whenever and wherever the context so requires. Additionally,
      unless the context requires otherwise, "or" is not exclusive.

     

    IN
      WITNESS WHEREOF, the parties hereto have duly executed this Agreement, or caused
      this Agreement to be duly executed by their respective officers, partners or
      other representatives, thereunto duly authorized, all as of the day and year
      first above written.

     

    
      	 	 	 
	 	COUGAR
              BIOTECHNOLOGY, INC.
	 
 	 
 	 
 
	 	By:  	/s/ David
              M.
              Tanen
	 	
               

              Name:  

            	
              
David
              M. Tanen 
	 	Title:	President

    

     

    
      
        	 	 	 
	 	 	 
	 	HORIZON
                BIOMEDICAL
                INVESTMENTS, LLC
	 
 	 
 	 
 
	 	By:  	/s/ Lindsay
                A. Rosenwald, M.D.
	 	
                 

                Name:  

              	
                
Lindsay
                A. Rosenwald, M.D.
	 	Title:	Managing
                Member
	 	 	
                Horizon
                  Biomedical Investments, LLC

                787
                  Seventh Avenue, 48th
                  Floor

                New
                  York, NY 10019

              
	 	 	 
	 	EIN#:	 

      

    

     

     

    
      	
              NUMBER
                OF SHARES OF

            	 
	
              COMMON
                STOCK

            	 
	
              PURCHASABLE:

            	
              4,250,000

            
	
              PURCHASE
                PRICE:

            	
              $
                750,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]